BBIO

BridgeBio Pharma, Inc. Common Stock

69.73

USD

BBIO Earnings Reports

Positive Surprise Ratio

BBIO beat 8 of 27 last estimates.

30%

Next Report

Date of Next Report

Apr 27, 2026

Estimate for Q1 26 (Revenue/ EPS)

$181.81M

-$0.70

Implied change from Q4 25 (Revenue/ EPS)

+17.92%

-30.00%

Implied change from Q1 25 (Revenue/ EPS)

+55.88%

-20.45%

BridgeBio Pharma, Inc. Common Stock earnings per share and revenue

On Feb 24, 2026, BBIO reported earnings of -1.00 USD per share (EPS) for Q4 25, missing the estimate of -0.75 USD, resulting in a -32.10% surprise. Revenue reached 154.18 million, compared to an expected 149.78 million, with a 2.94% difference. The market reacted with a +2.95% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.70 USD, with revenue projected to reach 181.81 million USD, implying an decrease of -30.00% EPS, and increase of 17.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Taysha Gene Therapies, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.09

Actual

-$0.08

Surprise

+18.45%

Assembly Biosciences, Inc

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.66

Actual

$2.48

Surprise

+474.06%

Sol-Gel Technologies Ltd. Ordinary Shares

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.39

Actual

Surprise

FAQ

What were BridgeBio Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, BridgeBio Pharma, Inc. Common Stock reported EPS of -$1.00, missing estimates by -32.1%, and revenue of $154.18M, 2.94% above expectations.

How did the market react to BridgeBio Pharma, Inc. Common Stock's Q4 2025 earnings?

The stock price moved up 2.95%, changed from $76.84 before the earnings release to $79.11 the day after.

When is BridgeBio Pharma, Inc. Common Stock expected to report next?

The next earning report is scheduled for Apr 27, 2026.

What are the forecasts for BridgeBio Pharma, Inc. Common Stock's next earnings report?

Based on 13 analysts, BridgeBio Pharma, Inc. Common Stock is expected to report EPS of -$0.70 and revenue of $181.81M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.